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Abstract  56 
 57 
Background 58 
Long-term toxicities from current treatments are a major issue in pediatric cancer. Previous 59 
studies, including our own, have shown prognostic value for the presence of PAX3/7-FOXO1 60 
fusion genes in rhabdomyosarcoma.  It is proposed to introduce PAX3/7-FOXO1 positivity as 61 
a component of risk stratification, rather than alveolar histology, in future clinical trials. 62 
Procedure 63 
To assess the potential impact of this reclassification, we have determined the changes to 64 
risk category assignment of 210 histologically reviewed patients treated in the UK from 65 
previous MMT (Malignant Mesenchymal Tumor) clinical trials for non-metastatic 66 
rhabdomyosarcoma based on identification of PAX3/7-FOXO1 by fluorescence in situ 67 
hybridization and/or reverse transcription PCR. 68 
Results 69 
Using fusion gene positivity in the current risk stratification would re-assign 7% of patients to 70 
different EpSSG (European Paediatric Soft Tissue Sarcoma Study Group) risk subgroups. 71 
The next European trial would have 80% power to detect differences in event free survival of 72 
15% over 10 years and 20% over 5 years in reassigned patients.  This would decrease 73 
treatment for over a quarter of patients with alveolar histology tumors that lack PAX3/7-74 
FOXO1. 75 
Conclusions 76 
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Fusion gene status used in stratification may result in significant numbers of patients 77 
benefitting from lower treatment associated toxicity. Prospective testing to show this 78 
reassignment maintains current survival rates is now required and is shown to be feasible 79 
based on estimated recruitment to a future EpSSG trial. Together with developing novel 80 
therapeutic strategies for patients identified as higher risk, this may ultimately improve the 81 
outcome and quality of life for patients with rhabdomyosarcoma.    82 
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Introduction 83 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, with ~450 84 
children and adolescents newly diagnosed each year in Europe (countries which report data 85 
to the Automated Childhood Cancer Information System, ACCIS1,2). The substantial 86 
improvement in survival rate for RMS patients that occurred from 1960 to 1996 with the 87 
advent of chemotherapeutic agents has largely stagnated with an estimated 5 year survival 88 
rate of 72%3,4. The reality remains that while the majority of children suffering from cancer 89 
will survive to adulthood, more than 80% of these will develop a serious or life threatening 90 
chronic health condition by the age of 45 as a result of their curative treatment5. Accurate 91 
risk determination in RMS patients is a priority to enable safe reduction of treatment intensity 92 
for those at lower risk and identify those at highest risk of succumbing to their disease who 93 
could benefit from treatment intensification and/or novel therapeutic strategies.   94 
 95 
Current clinical trials for RMS in Europe and the US use histological subtype alongside other 96 
clinical parameters including age at diagnosis, site and size of primary tumour, extent of 97 
residual disease after surgery, node involvement, and metastases to allocate patients to a 98 
risk group which will determine treatment intensity 6. Two main histological subtypes are 99 
recognised, embryonal (ERMS) which typically has a better prognosis than the alveolar 100 
(ARMS) “unfavourable histology” subtype.  The majority (70-80%) of ARMS cases have 101 
translocations resulting in fusion of the PAX3 or PAX7 gene with FOXO1 7,8. The resultant 102 
fusion proteins are novel transcription factors and considered key drivers of tumorigenesis9. 103 
 104 
Previous studies including large-scale expression profiling have revealed that ARMS 105 
tumours lacking characteristic fusion genes are molecularly and clinically indistinguishable 106 
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from ERMS tumors10,11. This is consistent with several studies, including a recent 107 
prospective assessment, that show a prognostic value for the fusion genes 12–15 although 108 
some issues with the representativeness of sample cohorts are also reported16,17. Based on 109 
the consensus view from these studies, that fusion gene presence rather than alveolar 110 
histology per se contributes to poorer outcome, it is proposed to incorporate fusion-gene 111 
status, rather than histology, into risk stratification of RMS. In order to address the impact of 112 
such a change in non-metastatic patients, we used the current EpSSG RMS2005 trial 113 
framework for risk stratification and applied this to a large cohort of well-annotated RMS 114 
cases enrolled in the series of Malignant Mesenchymal Tumour (MMT) trials, which we 115 
subjected to histopathological re-review. The treatment and outcome for patients in these 116 
trials were similar 18,19 and therefore were considered suitable for analysis as a single cohort.   117 
 118 
Here we report the impact of adopting fusion gene status in place of histology as part of 119 
RMS risk stratification. This has allowed us to estimate the proportion of patients that would 120 
change risk group and the power of future clinical trials to assess any adverse changes in 121 
patient outcome.  122 
 123 
Materials and Methods 124 
Pathology and tissue microarray construction 125 
Formalin fixed paraffin embedded (FFPE) samples from UK patients enrolled on the MMT89, 126 
MMT95 and MMT98 trials from the International Society of Paediatric Oncology (SIOP) were 127 
collected from multiple UK centres (Local Research Ethics Committee protocol 1836 and 128 
Multi-Regional Research Ethics Committee/98/4/023). Our cohort was subjected to 129 
histological re-review (A.K.) to apply current histological classification criteria20. Cases with 130 
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mixed histologies but containing true alveolar histology (classical and solid variant patterns) 131 
were considered to be ARMS. Clinical parameters were accessed from trial databases21. 132 
These and updated histological subtypes of samples from cases non-metastatic at 133 
diagnoses (stage I-III) are summarised in Table 1, and were representative of other RMS 134 
cohorts12. A smaller cohort of metastatic cases (summarised in Supplemental Table S1) was 135 
used separately for additional analyses. Moreover, outcomes from MMT89 and MMT95 136 
cases used in this study were representative of their respective trials (MMT89; Overall 137 
survival (OS) 74.4%, Event Free survival (EFS) 62.6%, MMT95; OS 74.3%, EFS 64% at 5 138 
years)18,19 (Outcome data shown refers to the cohort used in this study). The histopathologic 139 
diagnoses of the cases studied are also considered largely representative of the cases on 140 
the MMT89, MMT95 and MMT98 trials. 141 
 142 
Haematoxylin and eosin stained slides were marked for regions of tumour and a tissue 143 
microarray (TMA) constructed containing 1,863 cores representing RMS tumour from 329 144 
patients. This involved taking 0.6mm cores from tumour-containing regions of donor blocks 145 
and insertion into a recipient array block. There was an average of 6 cores per sample 146 
(range 1-24).  RMS cell lines negative and positive for each fusion gene (RD (negative)22, 147 
RH30 (PAX3-FOXO1)23, RMZ-RC2 (PAX7-FOXO1)24) were formalin fixed, paraffin 148 
embedded and cores inserted into each array block to act as controls. Sources and culturing 149 
conditions for cell lines have been previously described 25. 150 
 151 
Fusion gene status assessment by fluorescence in situ hybridisation 152 
Fluorescence in situ hybridisation (FISH) was performed on the TMA slides to determine 153 
whether samples carried a PAX3-FOXO1 or PAX7-FOXO1 fusion gene or neither.  Bacterial 154 
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artificial chromosome (BAC) DNA probes were identified that hybridize to the 5’ end of PAX3 155 
and PAX7 and to the 3’end of FOXO1. BAC DNA was amplified and subsequently purified 156 
using the Genomiphi Kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK) according to 157 
manufacturers instructions. BACs used for PAX3 were RP11-81I8, RP11-16P6 and RP11-158 
612G6 (labelled with Digoxygenin (DIG) (Roche, Basel, Switzerland) by random priming and 159 
indirectly detected using fluorescein isothiocyanate (FITC)-conjugated anti-DIG antibodies 160 
(Thermo Fisher Scientific, Waltham, MA, USA)). BACs used for PAX7 were RP11-468NG, 161 
CTD-2009F7 and RP11-121A23 (directly labelled using FISHBright® Aqua and the 162 
FISHBright® Nucleic Acid Labelling Kit (Leica Microsystems, Wetzlar, Germany)) and BACs 163 
used for FOXO1 were RP11-452K11, RP11-805F18 and RP11-350A18 (labelled with biotin 164 
by random priming and indirectly detected using Cy3-conjugated Streptavidin (Thermo 165 
Fisher Scientific)). All labelled BACs were individually hybridized to normal metaphase 166 
chromosomes to ensure their correct chromosomal location. FISH was carried out on TMA 167 
sections as previously described26. Slides were scanned using an Ariol slide scanner (SL-50) 168 
(Leica Microsystems) and each core was independently scored for fused red/green and 169 
red/aqua signals in a minimum of 50 non-overlapping tumour nuclei by 2 independent 170 
observers. Fused signals, less than a signal width apart, were required to be present in at 171 
least 10% of scorable nuclei for a core to be considered fusion gene positive. 172 
 173 
Fusion gene status assessment by reverse transcription-PCR 174 
In addition to preparing TMAs, we also cut 10-micron FFPE sections for a subset of samples 175 
where sufficient material was available.  These were assessed for fusion gene status by 176 
reverse transcription (RT)-PCR. RT-PCR results were used to confirm FISH results or 177 
provide a result in the event that FISH hybridisation for a patient was not successful. RNA 178 
was extracted from the FFPE rolls using the RecoverAll Total Nucleic Acid Isolation Kit for 179 
  
 
This article is protected by copyright. All rights reserved. 
 
10 
FFPE (Thermo Fisher Scientific) according to manufacturers’ instructions. Reverse 180 
transcription was subsequently carried out on up to 1 g of total RNA using the High 181 
Capacity Reverse Transcription Kit (Thermo Fisher Scientific). cDNA was then amplified in 182 
triplicate by real-time quantitative RT-PCR using Taqman  (Thermo Fisher Scientific) 183 
reagents for PAX3-FOXO1, PAX7-FOXO1 and Beta-2-microglobulin (B2M) expression, the 184 
latter acting as a reference gene. The primer sequences used in these assays have been 185 
previously described 27. Each assay was performed separately and cDNA from control cell 186 
lines (as indicated above) (no fusion gene, PAX3-FOXO- and PAX7-FOXO1-positive) was 187 
included in each run. Samples were designated fusion gene positive if amplification occurred 188 
for the relevant assay whereas samples were only designated fusion gene negative if no 189 
amplification was seen for either fusion gene assay and the signal from the B2M assay was 190 
not reached in less than or equal to 30 cycles. 191 
 192 
Survival analysis was evaluated using the Mantel-Cox log rank test, Mantel-Haenszel 193 
Hazard Ratio and Kaplan-Meier plots. 194 
 195 
Results 196 
Ascertainment of fusion gene status in TMA cohort 197 
Using FISH and/or RT-PCR analysis, fusion gene status was successfully determined in 210 198 
patients with non-metastatic disease and a smaller cohort of 50 patients with metastasis that 199 
were treated on MMT clinical trials and had full clinical follow up data. 155 samples were 200 
assigned using FISH results only, 17 using PCR results only and 88 were assigned using 201 
both methods with complete concordance. The results are included in Table 2. We identified 202 
one patient described as having embryonal histology yet was found to harbour a PAX3-203 
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FOXO1 fusion gene (0.64% of all ERMS patients). 20 patients with ARMS histology were 204 
found to be fusion gene negative (37.7% of all ARMS patients), 5 of which had mixed 205 
histology with only areas of true alveolar histology20.  206 
 207 
Comparison between risk determined using histology or molecular fusion gene status 208 
Within the non-metastatic setting, Kaplan-Meier analysis demonstrated that there was no 209 
significant difference in overall (OS) or event free survival (EFS) between patients with 210 
ERMS and fusion negative ARMS in contrast to the fusion positive cases that showed a 211 
significantly poorer overall survival outcome than fusion negative (log rank test, chi square 212 
value 21.9, p<0.0001, HR 6.047 (95% CI 2.845-2.85)) (Fig 1).  This is consistent with 213 
previous studies, including our own11,12. The Kaplan-Meier plots for fusion positive cases 214 
divided into PAX3-FOXO1 and PAX7-FOXO1 (Supplemental Fig S1) shows no significant 215 
difference in survival between PAX7-FOXO1 cases and any other subgroup, although the 216 
numbers are low. In the metastatic cohort, the outcome of patients with fusion negative 217 
alveolar disease appeared to be as poor as fusion positive cases (Supplemental Fig S2a) 218 
although there is no statistical significance between ERMS and fusion negative ARMS 219 
groups, but the numbers of these metastatic cases are very low. We also assessed outcome 220 
of our non-metastatic cohort according to the current non-metastatic EpSSG risk groups 221 
(Supplemental Table S2, treatment protocol associated with risk groups is outlined in 222 
Supplemental Table S3) and showed that the survival rates for each risk group were as 223 
expected (Supplemental Fig S2b).   224 
 225 
In order to assess the impact of using fusion status rather than histology on patient risk 226 
stratification, we stratified all patients using i) histopathology, according to the EpSSG 2005 227 
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trial regimen using the re-reviewed histology (ERMS as favourable, ARMS as unfavourable) 228 
and ii) fusion status in place of histopathology (fusion negative as favourable, fusion positive 229 
as unfavourable). The risk group of each patient from each analysis was then compared. 230 
Using fusion gene status, 14 patients with fusion gene negative ARMS (26.4% of all patients 231 
with ARMS, 70% of fusion negative ARMS patients) changed risk group (5 moved from very 232 
high to high, 8 moved from high to standard, 1 moved from high to low). A summary of these 233 
changes using fusion gene status is shown in for risk groups in Table 3 and for subgroups in 234 
Supplemental Table S4.  Note in Supplemental Table S4, that although 6 patients changed 235 
risk subgroup from G to E, there was no change in overall risk group (high) and therefore no 236 
change in treatment strategy for those particular patients. These changes would result in 237 
reducing treatment intensity for 14/20 fusion negative ARMS.  238 
 239 
It is vital to assess the patients receiving less intense treatment as a result of the change in 240 
stratification in forthcoming trials to ensure that their clinical outcome is not compromised. 241 
Assuming a null hypothesis that patients with fusion negative ARMS with downgraded risk 242 
will have an identical EFS rate to patients with ERMS of 70%, we performed power 243 
calculations to estimate the total patient number needed to have 80% power to identify 244 
decreases in EFS in this group (Table 4). Based on the previous trial, we predict that the 245 
next EpSSG trial is expected to recruit ~125 patients with non-metastatic paediatric RMS per 246 
year. Using the frequencies found in this study, we estimate that the next trial will have 80% 247 
power to detect differences in EFS of 15% over 7 years and 20% over 5 years. 248 
 249 
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Discussion 250 
Assessment of the molecular features of tumours is increasingly required for accurate 251 
diagnoses, risk stratification and precision approaches to treatment decisions for patients.  252 
Previous studies, including our own, have shown a prognostic value for the presence of the 253 
fusion gene in RMS and it is proposed to introduce this as a molecularly unfavourable 254 
category, in place of alveolar histology, into future clinical trials. Here, our assessment of 210 255 
samples from previous clinical trials, that are representative of the trials as a whole, shows 256 
that overall this would affect assignment of patients to specific risk subgroups, reducing 257 
treatment for over a quarter of patients with alveolar histology and 7% of all non-metastatic 258 
RMS (it is noteworthy that the next European trial plans to intensify chemotherapy for the 259 
High and Very High risk groups, which is likely to increase treatment associated morbidity). 260 
This has potential to reduce long-term toxicities in these patients, which is important as such 261 
toxicities are a major issue in the majority of RMS patients that are cured of their disease28.   262 
 263 
Changes in the histopathological criteria used to discriminate between embyronal and 264 
alveolar histology have been updated over time, with the introduction in 1995 of a 265 
prognostically relevant classification system which determined that even focal alveolar 266 
histology should confer an ARMS diagnosis29 resulting in an increasing proportion of ARMS 267 
cases. More recently, a re-examination of these criteria noted that certain histological 268 
patterns may be mimicking ARMS30, leading to an artificially high rate of ARMS diagnosis. 269 
Despite our cohort being re-reviewed using current criteria, we observed a relatively high 270 
proportion of fusion negative ARMS (37.7%).  However, including patients with metastasis in 271 
our cohort reduced this proportion to 26.9% similar to other studies and may reflect the more 272 
metastatic behaviour of ARMS driven by the fusion protein 11,31. The range of proportions of 273 
fusion negative ARMS reported is underpinned by diagnostic uncertainty using 274 
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histopathological criteria in challenging cases, where informal use of the fusion gene status 275 
and other clinical parameters is guiding histological diagnoses. Standardizing use of 276 
molecular criteria in future trials is therefore highly desirable. 277 
 278 
We identified 1 out of 157 patients with ERMS to be PAX3-FOXO1 positive by both FISH 279 
and RT-PCR. Fusion positive ERMS cases have been reported before27 where PCR 280 
detection was used, notably all of these cases demonstrated diffuse myogenin staining, a 281 
feature associated with ARMS32. This suggests that there is a rationale to screen for fusion 282 
genes in all patients, as these patients may move from low to high-risk groups. Previous 283 
studies have reported that patients with tumours harbouring a PAX7-FOXO1 gene have a 284 
superior outcome compared to PAX3-FOXO111,12,33 however numbers are limited and this 285 
may be stage-dependent13. We only had 6 patient samples with a PAX7-FOXO1 gene in our 286 
cohort and therefore could not address this question adequately in this study. Rarer fusion 287 
gene variants are reported such as PAX3-NCOA1 and PAX3-NCOA234 in ARMS and ERMS, 288 
however the clinical significance of these are unclear. 289 
 290 
Stratifying RMS patients according to molecular rather than histopathological criteria will 291 
result in a proportion of fusion negative alveolar patients (26.4% of patients with ARMS in 292 
this study) receiving less intense treatment, being perceived to be at lower risk. It is 293 
important to establish that these patients will have a similarly favourable outcome as patients 294 
with ERMS when treated on the same protocol. Using data from our patient population, we 295 
have estimated that the expected number of patients recruited to the next EpSSG trial will be 296 
sufficient to detect changes in event free survival of 15% over 7 years and 20% over 5 years 297 
with 80% power. Patients with ERMS have an EFS of 70% at 5 years compared to fusion 298 
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positive ARMS with 36.1% at 5 years. It is anticipated that molecular features of RMS will be 299 
increasingly incorporated into risk stratification as there is evidence that MYOD1 mutations 300 
in sclerosing/spindle RMS35–37, CDK4 amplification38 and the MG5 gene signature in fusion 301 
negative RMS25,39 can all impact survival. 302 
 303 
Here we have determined the potential impact of using fusion gene status rather than the 304 
histopathological definition of alveolar histology as an adverse indicator in the risk-305 
stratification of RMS that is proposed for use in the next clinical trials. We show that a 306 
significant proportion of patients with non-metastatic RMS (7%) will be assigned to a 307 
different risk group and treatment protocol as a consequence of this change. It is expected 308 
that this will result in children being spared some of the considerable toxicities and late 309 
effects of intense therapy without compromising their chance of cure, in addition to the 310 
possibility of identifying fusion positive patients presenting with ERMS or RMS-NOS that will 311 
benefit from being considered as high-risk. 312 
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Figure Legends 443 
Fig 1. Overall survival  (A) and event free survival (B) in non-metastatic RMS patients 444 
grouped into ERMS fusion negative (ERMS FN), ARMS fusion negative (ARMS FN) and 445 
fusion positive patients (FP). 446 
 447 
Supplemental Figure Legends 448 
 449 
Supplemental Figure S1. Overall survival  (A) and event free survival (B) in non-metastatic 450 
RMS patients grouped into ERMS fusion negative (ERMS FN), ARMS fusion negative 451 
(ARMS FN), PAX3-FOXO1 and PAX7-FOXO1. 452 
 453 
Supplemental Figure S2. (A) Overall survival in metastatic (stage IV) RMS grouped into 454 
ERMS fusion negative (ERMS FN), ARMS fusion negative (ARMS FN) and fusion positive 455 
patients (FP). (B) Overall survival in non-metastatic RMS patients stratified into risk groups 456 
according to the current EpSSG RMS2005 clinical trial criteria. 457 
 458 
Supplemental Table Legends 459 
 460 
Supplemental Table S1. Clinical and molecular characteristics of the metastatic cohort. 461 
 462 
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23 
Supplemental Table S2. Risk Stratification for the EpSSG non-metastatic RMS study. 463 
Pathology: Favourable indicates embryonal histology including botryoid and spindle cell 464 
subtypes; Unfavourable indicates alveolar histology. Post surgical stage (IRS group): I 465 
indicates complete primary resection; II indicates microscopic residual or primary complete 466 
resection but N1; III indicates macroscopic residual. Site: Favourable indicates Orbit, 467 
Genitourinary (non bladder/prostate), Head and neck (non-parameningeal); Unfavourable 468 
indicates parameningeal, extremities, Genitourinary bladder/prostate and all other sites. 469 
Node Stage: N0 indicates no clinical or pathological node involvement; N1 indicates 470 
pathological node involvement. Size and Age: Favourable indicates tumour size less than or 471 
equal to 5 cm and age less than 10 years; Unfavourable indicates all other options (i.e. Size 472 
greater than 5 cm and/or age greater than or equal to 10 years). 473 
 474 
Supplemental Table S3. Treatment protocol for EpSSG RMS risk groups. Tumour 475 
assessment carried out between first and second course of frontline therapy. VA = 476 
Vincristine/Actinomycin;  477 
IVA = Ifosfamide/Vincristine/Actinomycin; RT = radiotherapy; IVADo = 478 
Ifosfamide/Vincristine/Actinomycin/Doxorubicin 479 
*only given if patient shows complete response (CR) to first course and has favourable age 480 
and tumour size. 481 
**If patient shows stable disease (SD) after first course, second line treatment (usually 482 
Carboplatin, Cyclophosphamide, Topotecan or Doxorubicin) with radiotherapy will be given. 483 
***Randomised trial arms. 484 
 485 
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 486 
Supplemental Table S4. Summary of changes in subgroup between histological and 487 
molecular categorization of pathology. Hist. = Histology; Mol. = Molecular. Note that grey 488 
boxes indicate patients that remain in the same risk group using either histological or 489 
molecular categorization. 490 
 491 
TABLE 1 Clinical characteristics of the non-metastatic cohort 
 
Histology ERMS 157 
 ARMS 53 
Median age at diagnosis (years)  4.5 
Age at dx <10 173 
 >=10 37 
IRS group 1 28 
 2 40 
 3 142 
Size of primary tumour <=5cm 90 
 >5cm 115 
 unknown 5 
Site of primary tumour Favourable 83 
 Unfavourable 127 
Median follow up time (years)  8.1 
Patient Survival Alive  151 
 Dead 59 
Total no of patients  210 
  492 
 493 
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TABLE 2 Fusion gene status of the non-metastatic patient cohort, grouped by 
histology 
 
 ERMS ARMS Total 
Negative 156 20 176 
PAX3-FOXO1 1 27 28 
PAX7-FOXO1 0 6 6 
Total 157 53 210 
  494 
 495 
 496 
TABLE 3 Summary of changes in EpSSG risk group between histological and 
molecular categorization of pathology 
 
Risk 
Group 
Subgroup Histology Risk 
group 
Molecular Risk 
group 
% 
change 
Low A 9 10 +11.1 
Standard B  
70 
 
 
78 
 
+11.4 C 
D 
High E  
117 
 
113 
 
-3.4 F 
G 
Very High H 14 9 -35.7 
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TABLE 4 Estimation of the number of patients needed for 80% power to 
detect decreased EFS rate in fusion gene negative alveolar patients with 
downgraded risk 
 
Change in EFS rate No of downgraded 
patients with ARMS FN  
Total patient number 
10% 141 2,015 
15% 63 900 
20% 36 515 
25% 23 329 
 
  500 
 501 
 502 
 503 
